...
GILDLARGE

Gilead Sciences, Inc.

HealthcareDrug Manufacturers - General
$148.95
$0.05(+3.60%)
52W$93.37
$157.29
FinancialsValuationvs ABBV
Updated Mar 2, 12:00 AM
RSI49
RS Rating80/99
Beta0.38
Volatility29%
F-Score7/9
Mkt Cap$185.6B
STAGE 2 UPTREND

Price Action

5Y Daily
50 DMA150 DMA200 DMA

Technical Summary

STAGE 2 UPTREND

Gilead Sciences, Inc. is in a confirmed Stage 2 uptrend, with price holding above all major moving averages and trend structure remaining intact. Relative strength is leading (RS Rating: 80), indicating clear outperformance against the broad market. Earnings growth of 23% provides fundamental context to the price action. Momentum will need to be maintained above the 50-day moving average to sustain this leadership phase.

Relative Strength
80
out of 99
Market Leader
Trend Score
4/4
Minervini Criteria
STAGE 2 UPTREND
Risk (Beta)
0.38
vs S&P 500
LOW VOL
52W Position
87%
from 52W low
Near High
Trend & Momentum Analysis

Trend Template (Minervini)

STAGE 2 UPTREND4/4 Criteria Met
CriterionValueStatus
Price > 50 SMA$135.57
50 SMA > 100 SMA$128.72
100 SMA > 150 SMA$123.94
150 SMA > 200 SMA$120.30

Price vs Moving Averages

PeriodValueSpreadSignal
20 SMA$149.23-0.19%BELOW
50 SMA$135.57+9.87%ABOVE
100 SMA$128.72+15.71%ABOVE
150 SMA$123.94+20.18%ABOVE
200 SMA$120.30+23.81%ABOVE

Price Performance

1D+3.6%
1W-0.6%
1M+6.6%
3M+18.4%
6M+32.3%
YTD+22.5%
1Y+30.3%
3Y+22.8%
52-Week Trading Range87% from low
$148.95
52W Low$93.37
52W High$157.29

Technical Indicators

RSI (14)NEUTRAL
48.8
305070
VCP ScoreWARM
6/10
Base depth: 27.1%

Risk Profile

Beta
0.38
52W Vol
29%
ATR
$4.25
Max DD (1Y)
-17%

Volume Analysis

Today
148
50D Avg
6.20M
Vol Ratio
0.00x
Liquidity
VERY LIQUID

Earnings Momentum

Q1'25+131%
$1.04
Q2'25+21%
$1.56
Q3'25+143%
$2.43
Q4'25+23%
$1.74
Fundamentals & Growth

Growth Trends

Compounded Sales Growth

10 Years:+1.45%
5 Years:+5.08%
3 Years:+1.74%
TTM:+2.40%

Compounded Profit Growth

10 Years:-25.64%
5 Years:-38.21%
3 Years:-57.44%
TTM:+17.30%

Stock Price CAGR

10 Years:+5.49%
5 Years:+18.98%
3 Years:+22.75%
1 Year:+30.30%

Return on Equity

10Y Avg:32.9%
5Y Avg:16.4%
3Y Avg:16.6%
Last Year:37.6%

Key Metrics

Market Cap$185.6B
Gross Margin78.3%
Net Margin1.7%
Piotroski F-Score7/9

More GILD Analysis

Full Financial AnalysisDCF & Intrinsic ValueTotal Return Calculator

Compare With

GILD vs ABBVABBVAMGNNVOBIIB

Data Dictionary

RS Rating (Relative Strength)

Measures 12-month price performance vs all stocks. Rating of 80 meansGILD outperformed 80% of all stocks. Scores >80 indicate market leaders.

Beta

Measures volatility vs S&P 500. Beta of 0.38 means 62% less volatile than market.

Piotroski F-Score

9-point financial strength score based on profitability, leverage, and efficiency. Score of 7/9. Scores 7-9 = strong, 4-6 average, 0-3 = weak.

VCP (Volatility Contraction Pattern)

Measures base formation quality. Higher scores indicate tighter consolidation near pivot points. Score of 6/10 with WARM status.

Frequently Asked Questions

Is GILD in an uptrend right now?

GILD has a trend score of 4/4 based on Minervini's Stage Analysis. Yes, GILD is in a Stage 2 uptrend with price above all major moving averages (50, 100, 150, 200 SMA) properly stacked.

Is GILD overbought or oversold?

GILD's RSI (14) is 49. The stock is in neutral territory, neither overbought nor oversold.

Is GILD outperforming the market?

GILD has a Relative Strength (RS) Rating of 80 out of 99. Yes, GILD is a market leader, outperforming 80% of all stocks over the past 12 months.

Where is GILD in its 52-week range?

GILD is trading at $148.95, which is 95% of its 52-week high ($157.29) and 87% above its 52-week low ($93.37).

How volatile is GILD?

GILD has a Beta of 0.38 and 52-week volatility of 29%. It's less volatile than the S&P 500 - generally more stable.